CRPS-RISE Outcomes Registry
A Prospective Longitudinal Outcomes Registry of Complex Regional Pain Syndrome Type 1 (CRPS-1) in Participants Treated With Neridronate in the CRPS-RISE Trial and/or Open-Label Extension (OLE)
The goal of this observational study is to learn about how well neridronate keeps working in the months after treatment. For 12 or up to 24 months while the registry is open participants will answer online survey questions about their CRPS pain, medication use or procedures done and how CRPS affects what they are able to do.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Detailní popis
The primary objective of the registry is to evaluate the long-term effectiveness of IV neridronate across three outcome domains in participants who qualified in CRPS-RISE with early, warm CRPS-1 and a positive triple phase bone scan, following prior treatment with four infusions of neridronate 100 mg IV over approximately a 10-day period. The three outcome domains include, patient report of health status, CRPS-1 related clinical events, and disability status.
No neridronate treatment will be given as part of the registry and limited safety information will be collected. Participants will have received neridronate either through CRPS-RISE and/or through the Open Label Extension.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: CRPS-RiseRegistry
- Telefonní číslo: 877-834-5183
- E-mail: CRPS-RiseRegistry@iqvia.com
Studijní místa
-
-
North Carolina
-
Durham, North Carolina, Spojené státy, 27703
- Nábor
- CRPS-RISERegistry
-
Kontakt:
- CRPS-RiseRegistry CRPS-RiseRegistry
- Telefonní číslo: 877-834-5183
- E-mail: CRPS-RiseRegistry@iqvia.com
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
The registry target population for provisional enrollment includes all participants in CRPS-RISE, the parent trial of the Registry. After the completion of the last participant's last visit in CRPS-RISE and the unblinding of the trial, the Enrolled Study Cohort will be participants confirmed to have completed a four-infusion course of neridronate. The Enrolled Study Cohort will also include participants in the Open Label Extension study.
Popis
Inclusion Criteria:
-
Participants from CRPS-RISE
-
Completion of four infusions of IP (neridronate 100 mg over a ~ 10-day period [or the renally modified dosing, as applicable] or placebo) in CRPS-RISE .
-
Completed CRPS-RISE with a final trial visit at Week 6 (Visit 8) or later.
Participants who meet both criteria will be provisionally enrolled pending post-trial unblinding and be included in the Provisionally Enrolled Study Cohort.
After CRPS-RISE last patient last visit unblinding, only participants who meet the following neridronate exposure criterion #3 will continue in registry follow-up and be included in the Enrolled Study Cohort:
-
Completion of 4-infusions of neridronate 100 mg over approximately a 10-day period in CRPS-RISE.
-
-
Participants from the Open Label Extension (OLE)
- Completion of 4 infusions of neridronate 100 mg over approximately a 10-day period (or the renally modified dosing, as applicable) in the OLE.
- Completed OLE with a final trial visit at Week 6 (Visit 8) or later.
Exclusion Criteria:
There are no exclusion criteria.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: CASE_ONLY
- Časové perspektivy: PROSPECTIVE
Počet skupin / kohort
Kohorty a intervence
Skupina / kohortaSkupina / kohorta |
|---|
|
Provisionally Enrolled Study Cohort
Participants provisionally enrolled in the registry. (Note: Participants provisionally enrolled who do not meet this neridronate-exposure criterion will not continue registry follow-up.) |
|
Enrolled Study Cohort
Participants who have consented to participate and meet all inclusion criteria including confirmation of completing four infusions of neridronate. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change from baseline to each registry assessment of average pain in the past 24 hours.
Časové okno: Every 3 months from enrollment until up to 2 years after entry.
|
Average pain (24-hour recall) reported on an 11-point numeric rating scale. This is recorded every 90 days from entry. |
Every 3 months from enrollment until up to 2 years after entry.
|
|
Time to loss of benefit where benefit is 50% reduction in average pain intensity from baseline to Week 12 of the CRPS-RISE trial.
Časové okno: Every 3 months from enrollment until up to 2 years after entry.
|
Each patient reported registry assessment of average pain in the past 24 hours will use an 11 point numeric rating scale. The analysis will be limited to participants who experienced benefit. Data will be summarized as Kaplan-Meier estimates. |
Every 3 months from enrollment until up to 2 years after entry.
|
|
Change from baseline to each registry assessment in CRPS Severity Score Self-Report (CSS-SR) total score and individual items.
Časové okno: Every 3 months from entry to up to 24 months of participation.
|
The CSS-SR is designed as a patient self-report questionnaire to assess the severity of CRPS signs and symptoms using plain language to assess 13 concepts. |
Every 3 months from entry to up to 24 months of participation.
|
|
Change from baseline to each registry assessment in Patient Global Impression of Severity (PGI-S).
Časové okno: Every 3 months from enrollment until up to 2 years after entry.
|
The 6-point PGI-S is an overall assessment of the participant's perception of the severity of their CRPS condition at the time of the assessment. Participants will respond to the question "How would you rate the symptoms of your CPRS at this time." Possible responses are scored from 0 to 5 representing none, minimal, mild, moderate, severe, very severe. |
Every 3 months from enrollment until up to 2 years after entry.
|
|
Change from baseline to each registry assessment in each of the Short Form 12 Health Survey (SF-12, Acute Version 2) domains, Physical Component Score (PCS), Mental Component Score (MCS), and individual items.
Časové okno: Every 3 months from enrollment until up to 2 years after entry.
|
The SF-12 is a widely used measure of general health status used in observational studies across a broad range of disease areas. It is a shortened version of the SF-36 V2.0 and yields 8 domain scores and a Physical Component Summary and Mental Component Summary. Each domain score is calculated by transforming raw responses to a 0-100 scale, where higher scores indicate better health status. |
Every 3 months from enrollment until up to 2 years after entry.
|
|
Change from baseline to each registry assessment in Daily Sleep Interference Scale (DSIS) in the past 24 hours on an 11-point numeric rating scale.
Časové okno: Every 3 months from enrollment until up to 2 years after entry.
|
The DSIS is a single-item scale that assesses "how much did your pain interfere with your sleep during the past 24 hours?" (0 = did not interfere; 10 = completely interfered |
Every 3 months from enrollment until up to 2 years after entry.
|
|
CRPS-1 Related Clinical Events during the 3 months preceding each registry assessment.
Časové okno: Every 3 months from enrollment until up to 2 years after entry.
|
The CRPS-1 Treatment Checklist was developed for this registry to assess commonly used pharmacologic treatments (e.g., opioids, neuropathic pain agents, ketamine, NSAIDs, bisphosphonates, corticosteroids, and topicals),interventional procedures (e.g., spinal cord or dorsal root ganglion stimulation, peripheral nerve stimulation, stellate/lumbar sympathetic blocks, sympathetic ablation/sympathectomy, intrathecal pump implant, and Bier block), and non-invasive rehabilitation therapies (e.g., physical therapy, occupational therapy, mirror visual feedback, psychological therapies, scrambler therapies or acupuncture). Participants select all CRPS-related treatments used in the past 3 months. The checklist will also record participation in the open-label clinical trial and is intended for descriptive evaluation of long-term CRPS-1 treatments with a focus on resource intensive events. The outcome domain assesses the long-term effectiveness of neridronate through patient reports. |
Every 3 months from enrollment until up to 2 years after entry.
|
|
Disability Status
Časové okno: Every 3 months from enrollment until up to 2 years after entry.
|
During the 3 months preceding each registry assessment the participant reported applying for or being on short-term disability, long-term disability, or workers compensation. As a binary endpoint, it will be summarized as frequencies and percentages. The domain assesses the long-term effectiveness of neridronate through patient reports of short-term disability, long-term disability, and workers compensation. |
Every 3 months from enrollment until up to 2 years after entry.
|
Další výstupní opatření
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Healthcare Use and Costs (Provisional)
Časové okno: Every 3 months from enrollment until up to 2 years after entry.
|
The potential for inclusion of linked health care claims and electronic health record data will be enabled by having participants consent to tokenizing their identifying information. |
Every 3 months from enrollment until up to 2 years after entry.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Joel Castellanos, MD, UCSD
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- AMBTX-01-R01
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .